Company Overview

Psychemedics Corporation (NASDAQ: PMDI) is a U.S.-based clinical laboratory company specializing in hair-based drug testing services. The company operates within the drug testing and diagnostics industry, serving employers, government agencies, and other organizations that require substance abuse detection and monitoring. Psychemedics is primarily known for its proprietary hair testing technology, which is positioned as an alternative to urine and oral fluid testing by offering a longer detection window for drug use.

The company’s core revenue is generated from laboratory testing services, including pre-employment, random, and post-incident drug testing programs. Psychemedics serves corporate clients, transportation companies, law enforcement agencies, and international customers through distributors. Founded in 1987, the company pioneered the commercial application of hair analysis for drug detection and became publicly traded in 1996, establishing itself as one of the earliest and most recognized providers in this niche segment.

Business Operations

Psychemedics operates as a single-reportable-segment company focused on drug testing services, with its primary business centered on hair drug testing services. Revenue is generated through laboratory analysis performed at its wholly owned testing facilities, using proprietary methodologies designed to detect various controlled substances. The company emphasizes its patented technology and standardized laboratory processes as key operational assets.

Operations are primarily based in the United States, with laboratory facilities in Texas and corporate headquarters in Massachusetts. International business is conducted through distribution relationships rather than owned laboratories. Psychemedics does not report material joint ventures but works with third-party collection sites, resellers, and distributors to expand market access.

Strategic Position & Investments

The company’s strategic focus centers on expanding adoption of hair testing as a preferred method for workplace drug testing, particularly in regulated and safety-sensitive industries. Growth initiatives have historically emphasized increasing penetration among large employers, transportation companies, and government-related entities, while maintaining pricing discipline and operational efficiency.

Psychemedics has historically pursued limited acquisition activity, focusing instead on organic growth and protection of its intellectual property portfolio. Investment priorities have included laboratory automation, quality control systems, and legal defense of proprietary testing methodologies. Public disclosures do not indicate material investments in unrelated sectors or emerging technologies outside the drug testing and diagnostics space. Data inconclusive based on available public sources regarding recent material acquisitions or portfolio investments.

Geographic Footprint

Psychemedics’ operational footprint is concentrated in North America, with its headquarters in the United States and laboratory operations supporting domestic clients nationwide. The company maintains testing and logistical capabilities designed to serve employers across all U.S. states through centralized laboratory infrastructure.

Internationally, Psychemedics has a presence in parts of Europe, Asia-Pacific, and Latin America through distribution and licensing arrangements. These regions represent a smaller portion of total revenue compared to the U.S. market, but they provide strategic exposure to multinational employers and international drug testing programs.

Leadership & Governance

Psychemedics is led by an executive team with experience in laboratory operations, corporate management, and regulated service industries. Leadership has emphasized operational reliability, scientific credibility, and legal defensibility of the company’s testing methods as core elements of its strategic vision.

Key executives include:

• Raymond C. Kubacki – Chairman of the Board
• John J. Gavigan – Chief Executive Officer
• Kerry A. Shoemaker – Chief Financial Officer
• Michael C. Watterson – Chief Operating Officer

The company operates under a board-led governance structure typical of publicly traded U.S. laboratory services firms, with oversight informed by regulatory compliance requirements and shareholder accountability.